iTeos Therapeutics, Inc.

ITOSDelisted Aug 29, 2025

Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001808865

SEC filings (opens in a new tab)

iTeos Therapeutics, Inc. was delisted on Aug 29, 2025; its insiders filed their last Form 4 on Aug 29, 2025; 137 institutions reported holding it in 13F filings for Q2 2025, worth $377.0M in total; no superinvestor held it.

Q2 2024 vs. Q1 2024

How the institutions holding iTeos Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024 All holders in Q1 2024

13F holders of ITOS: Q1 2024 compared with Q2 2024
Measure	Q1 2024	Of which not filed for Q2 2024	Q2 2024	Change
Holders	136	1	139	+4
Shares	34.6M	26.7K	36.2M	+1.64M (+4.8%)
Value	$471.2M	$363.7K	$536.8M	+$65.9M (+14.0%)

1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (23)

Institutions that held iTeos Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to ITOS in Q2 2024
Institution	Shares	Value	% of portfolio
Vestal Point Capital, LP	1,750,000	$26.0M	1.94%
Candriam Luxembourg S.C.A.	509,303	$7.56M	0.05%
Jane Street Group, LLC	159,855	$2.37M	0.00%
Clearline Capital LP	156,894	$2.33M	0.20%
ADAR1 Capital Management, LLC	60,000	$890.4K	0.18%
Rafferty Asset Management, LLC	35,985	$534.0K	0.00%
UBS Oconnor LLC	35,323	$524.2K	0.01%
Fisher Asset Management, LLC	35,215	$522.6K	0.00%
Verition Fund Management LLC	31,714	$470.6K	0.00%
Jump Financial, LLC	25,784	$382.6K	0.01%
Y-Intercept (Hong Kong) Ltd	20,814	$308.9K	0.02%
Caption Management, LLC	19,000	$282.0K	0.03%
Two Sigma Advisers, LP	18,200	$270.1K	0.00%
Bank of Montreal	16,485	$249.3K	0.00%
Simplex Trading, LLC	16,083	$238.0K	0.01%
Mirae Asset Global ETFs Holdings Ltd.	14,371	$214.2K	0.00%
Corebridge Financial, Inc.	13,966	$207.3K	0.00%
Belvedere Trading LLC	13,758	$204.2K	0.01%
Pacer Advisors, Inc.	205	$3.04K	0.00%
SRS Capital Advisors, Inc.	95	$1.41K	0.00%
Nisa Investment Advisors, LLC	93	$1.38K	0.00%
Rothschild Investment LLC	10	$148	0.00%
Sofos Investments, Inc.	0	$148	0.00%

Sold out (19)

Institutions that held iTeos Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.

Institutions that sold out of ITOS in Q2 2024
Institution	Shares, Q1 2024	Value, Q1 2024
Braidwell LP	1,162,374	$15.9M
Acadian Asset Management LLC	244,712	$3.34M
Cubist Systematic Strategies, LLC	103,981	$1.42M
Massachusetts Financial Services Co	75,678	$1.03M
HRT Financial LP	50,936	$694.0K
Trexquant Investment LP	25,886	$353.1K
Lighthouse Investment Partners, LLC	24,473	$333.8K
Allianz Asset Management GmbH	20,542	$280.2K
Voya Investment Management LLC	20,312	$277.1K
Tudor Investment Corp Et Al	17,635	$240.5K
Prelude Capital Management, LLC	17,428	$237.7K
Gsa Capital Partners LLP	15,451	$211.0K
American International Group, Inc.	12,213	$166.6K
SG Americas Securities, LLC	9,614	$131.0K
Gladius Capital Management LP	3,383	$46.1K
Point72 Asia (Singapore) Pte. Ltd.	1,373	$18.7K
Metropolitan Life Insurance Co	1,365	$18.6K
Point72 (DIFC) Ltd	1,233	$16.8K
Nelson, Van Denburg & Campbell Wealth Management Group, LLC	5	$68

Not filed for Q2 2024 yet (1)

Institutions that held iTeos Therapeutics, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ITOS in Q1 2024 that haven't filed for Q2 2024
Institution	Shares, Q1 2024	Value, Q1 2024
Credit Suisse AG	26,661	$363.7K